The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
27-May-25
$100 million
Target:
Emergency Care Partners
Advised Emergency Care Partners (“ECP”), a leading provider of emergency department management services and its majority owner Varsity Healthcare Partners (“VHP”) on a growth recapitalization transaction, inclusive of a $100 million preferred equity investment led by MidOcean Partners (“MidOcean”)
08-May-25
Undisclosed
Target:
German Doner Kebab ("GDK")
Acquiror:
True
Advised Hero Brands on the strategic investment in GDK by True. GDK is a leading Middle Eastern quick-service restaurant brand, with over 145 franchised locations in the UK and 170 globally, including the US, Canada, Sweden and the Middle East
05-May-25
Pending
~$10 billion
Target:
Skechers U.S.A., Inc.
Acquiror:
3G Capital
Advising Skechers, the third largest footwear company in the world, on its sale to 3G Capital
28-Mar-25
Pending
$100 million
Target:
UK High Street business of WH Smith PLC
Acquiror:
Modella Capital
Advising WH Smith PLC, one of the UK’s leading retailers, on the sale of its UK High Street business
04-Feb-25
Pending
$1.1 billion
Target:
PRISM Vision Group
Acquiror:
McKesson Corporation
Advising PRISM Vision Group, a leading medical eye care services company, on its majority stake sale to McKesson Corporation, a diversified healthcare services and distribution leader
28-Jan-25
$219 million
Target:
The Container Store, Inc.
Advised the Ad Hoc Group of Term Loan Lender to The Container Store on its Pre Packaged Chapter 11 Restructuring
27-Nov-24
$618 million
Target:
Empire Today
Advised Empire Today, the largest and only national DTC provider of replacement hard surface flooring and carpet in the U.S., on its liability management transaction
13-Nov-24
Pending
Undisclosed
Target:
Centogene GmbH
Acquiror:
Charme Capital Partners
Advising Charme Capital Partners, a European mid-market private equity fund, on the acquisition of Centogene GmbH, a leading provider of pharmaceutical solutions and diagnostic tests for rare diseases
01-Jul-24
Undisclosed
Target:
Medical Review Institute of America
Acquiror:
Parthenon Capital
Advised Medical Review Institute of America, a portfolio company of Summit Partners and a leading provider of outsourced utilization management and clinical review solutions to payors, on its strategic growth investment from Parthenon Capital
26-Jun-24
Pending
$630 million
Target:
Haleon plc’s Nicotine Replacement Therapy Business (ex-US)
Acquiror:
Dr. Reddy’s Laboratories
Advising Haleon plc on the sale of its global nicotine replacement therapy business (ex-US) to Dr. Reddy’s Laboratories
20-Jun-24
Pending
$1.8 billion
Target:
CP Kelco
Acquiror:
Tate & Lyle
Advising Tate & Lyle plc, a UK-listed specialty food and beverage ingredients company, on the acquisition of CP Kelco, a US-based provider of pectin, speciality gums and other nature-based ingredients, from J.M. Huber Corporation
08-May-24
$800 million
Target:
U.S. Acute Care Solutions
Advised U.S. Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on the refinancing of its senior secured notes
01-May-24
Undisclosed
Target:
Functional Formularies
Acquiror:
Danone
Advised Danone on its acquisition of Functional Formularies, a leading whole foods tube feeding business in the US, from Swander Pace Capital
09-Apr-24
Undisclosed
Target:
Tegra’s Operating Entities in Honduras, El Salvador, and the U.S.
Acquiror:
SAE-A Trading
Advising Tegra, a premier and leading near and onshore apparel manufacturer for sport, team, and performance apparel, on the sale of its operating entities in Honduras, El Salvador, and the U.S. to SAE-A Trading, a vertically integrated textile and apparel garment manufacturer
16-Nov-23
~$400 million
Target:
Sonoma-Cutrer Vineyards (Brown-Forman)
Acquiror:
The Duckhorn Portfolio
Advised Brown-Forman, the largest American-owned spirits and wine company, on its sale of Sonoma-Cutrer Vineyards to The Duckhorn Portfolio
27-Sep-23
Undisclosed
Target:
Slayback Pharma LLC
Acquiror:
Azurity Pharmaceuticals
Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products
10-Aug-23
Undisclosed
Target:
Clinigen Ltd’s portfolio of Established Medicines
Acquiror:
CNX Therapeutics
Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners
14-Jul-23
$674 million
Target:
Juice Plus+
Advised Juice Plus+, a global health and wellness company in the direct selling space on a comprehensive recapitalization transaction
20-Jun-23
Pending
$595 million
Target:
Lookers Plc
Acquiror:
Alpha Auto Group
Advising JerseyCo, the indirect Holdco of Alpha Auto Group, a Canadian automotive dealership group, on its acquisition of Lookers Plc, a leading UK automotive dealership group
01-Jun-23
Pending
Undisclosed
Target:
Interest in Joint Venture with CarepathRx Health System Solutions
Acquiror:
The Cigna Group
Advising Cigna on its investment in CarepathRx Health System Solutions, under Evernorth, Cigna’s health services subsidiary
25-Apr-23
Pending
Undisclosed
Target:
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Acquiror:
Advanz Pharma (UK)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
20-Mar-23
Pending
Undisclosed
Target:
Clinigen Ltd’s Lamda Laboratories
Acquiror:
Adragos Pharma
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
16-Feb-23
Pending
$220 million
Target:
Flavor Specialty Ingredients division of IFF
Acquiror:
Exponent Private Equity
Sole financial adviser to Exponent, one of the UK’s leading private equity firms, on the acquisition of IFF’s Flavor Specialty Ingredients division, a global leader in the base aromas market
23-Jan-23
Pending
$200 million
Target:
Clinigen Ltd’s Proleukin
Acquiror:
Iovance Biotherapeutics
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma